MAXION Flexible Wheel with MICHELIN ACORUS Technology
Innovation has always been part of Michelin’s genetic code – driving mobility and tire developments for more than 100 years. Now with MICHELIN ACORUS Technology, in partnership with Maxion Wheels, Michelin is reinventing the wheel to help eliminate road-based damage to tires and rims.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912006833/en/
The Maxion Flexible Wheel with Michelin Acorus technology is a wheel designed and built to withstand the toughest road conditions for large diameter, low profile tires. (Photo: Business Wire)
The patented new technology, developed by Michelin and Maxion Wheels for the passenger car wheel market, incorporates two flexible rubber flanges mounted on a special wheel body to create a flexible wheel that improves the ride and comfort and also absorbs impacts from potholes and curbs. The new wheel is compatible with all tires on the market and comprises an alloy rim – which is narrower than normal, two rubber flanges and an optional cosmetic insert to protect the alloy wheel.
Talking about this new innovation, Michelin Chief Operating Officer, Florent Menegaux said: “Car wheels have been getting bigger and bigger, as they contribute to making cars look more premium, and large shiny alloys are an integral part of all modern car designs. However, the resulting low profile tires with short sidewalls are much more susceptible to damage on today’s deteriorating roads with myriad potholes.”
Pieter Klinkers, Maxion Wheels CEO stated: “This is a game changer for wheels; a standard wheel driven through a pothole can damage the tire and potentially crack the alloy rim, putting the safety of driver and passengers at risk. When the Maxion Flexible Wheel hits a pothole, the MICHELIN ACORUS Technology flange flexes and protects the tire and the wheel.”
In tests with a 285/30R21 tire driven through a pothole*, the standard rim version punctured the tire at 28kph whereas the Flexible Wheel with the MICHELIN ACORUS Technology did not puncture, or sustain damage at any speed.
In addition to damage reduction, safety and improved mobility, the Maxion Flexible Wheel with MICHELIN ACORUS Technology has other benefits for the driver. It helps overcome other shortcomings associated with low profile tires with short sidewalls – comfort and noise levels are both improved due to the flexible rubber flange which sits between the wheel and the tire. There is also an environmental benefit in using MICHELIN ACORUS Technology; the Flexible Wheel is designed to work with any brand of tire, including low rolling resistance tires – meaning lower CO2 emissions and better fuel economy. The innovative wheel solution also means fewer damaged tires and wheels are being thrown away following pothole damage.
MICHELIN ACORUS Technology is the product of Michelin’s research Group. The Incubator Program shortened the time to market by showing and testing it with customers. Having designed and developed this unique patented technology, Michelin started to work in partnership with Maxion Wheels, a leader in the wheel business, to bring the Flexible Wheel to market.
The name ACORUS is taken from Acorus Calamus, a wetland plant that looks like a reed, which features in a famous French fable ‘the oak and the reed’ with the wisdom that “a reed bends but does not break”. The Flexible Wheel not only safeguards against potholes and poor roads, but marks an end to the compromise in passenger car wheel design between robustness and premium look.
The Maxion Flexible Wheel with MICHELIN ACORUS Technology, launched at the Frankfurt IAA, will initially be sold in 19” and above sizes to the OE premium automakers by the partnership between MICHELIN and Maxion Wheels.
*80mm deep, 700mm long, 70° impact angle
About Maxion Wheels
Maxion Wheels, a division of IOCHPE-MAXION S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks and trailers. The Company also produces wheels for agriculture and military vehicles, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion is the world's largest wheel manufacturer, producing 56 million wheels per year. The Company serves its global OEM customers from 28 locations in 15 countries on five continents, and has state-of-the-art technical centers in the Americas, Europe and Asia. To learn more, please visit Maxion Wheels’ website at www.maxionwheels.com.
Michelin, the leading tyre company, is dedicated to enhancing its clients’ mobility, sustainably; designing and distributing the most suitable tyres, services and solutions for its clients’ needs; providing digital services, maps and guides to help enrich trips and travels and make them unique experiences; and developing high-technology materials that serve the mobility industry. Headquartered in Clermont-Ferrand, France, Michelin is present in 170 countries, has 111,700 employees and operates 68 production facilities in 17 countries which together produced 187 million tyres in 2016 (www.michelin.com).
Global Director, Marketing and Communications
Tel: +1 (734) 737-5204
Mobile: +1 (248) 916-2477
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third